Pangaea Oncology (PANG) | Stock Overview & Key Data
Pangaea Oncology Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €2.97 on November 13, 2017
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Pangaea Oncology
PANG
|
61.77M Small-cap | 1.18% | 1.18% | 2.99% | 1.18% | -0.58% | 3.61% | 17.01% | -25.22% | -31.20% | -31.20% | -31.20% |
|
Clinica Baviera S.A
CBAV
|
832.96M Mid-cap | -0.38% | 5.69% | 0.00% | 17.65% | 5.48% | 49.86% | 175.86% | 290.98% | 847.18% | 933.80% | 933.80% |
|
EuroEspes S.A
EEP
|
6.22M Small-cap | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.85% | -46.53% | -59.70% | -59.70% |
|
Grifols, S.A
GRF
|
6.09B Large-cap | -7.25% | 1.24% | -18.49% | -20.87% | -20.02% | 5.17% | -3.97% | -60.31% | -52.89% | 33.98% | 244.23% |
|
Laboratorios
ROVI
|
4.34B Large-cap | -4.70% | 3.25% | 11.63% | 25.93% | 28.02% | 58.55% | 101.84% | 68.26% | 449.09% | 1,459.62% | 743.04% |
|
Almirall S.A
ALM
|
2.76B Large-cap | -0.47% | 11.78% | -0.16% | 0.79% | -1.40% | 31.68% | 36.63% | -2.60% | -9.40% | 65.19% | -15.31% |
Ownership & Short Interest
Calculate Your Pangaea Oncology Investment Returns
Long-Term Investment Performance Analysis
Pangaea Oncology stock price in Sep 2017 was €2.50, A €1,000.00 lump sum investment in Pangaea Oncology made 8 years ago would be worth approximately €688.00 today, representing a negative return of -31.20%. This translates to an annualized return (CAGR) of -4.26%.
8 Years 7 Months Investment Scenario (Sep 2017 - Apr 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PANG's 52-week high and low?
- In the last 52 weeks, Pangaea Oncology reached a high of €1.75 (on January 22, 2026) and a low of €1.63 (on December 16, 2025).
- What is the market cap and P/E ratio for PANG?
- Curious about Pangaea Oncology's size and valuation? Its market capitalization stands at 61.77M. When it comes to valuation, the P/E ratio (trailing twelve months) is -50.34, and the forward P/E (looking ahead) is -54.67.
- Does PANG pay dividends? If so, what's the yield?
- As for dividends, Pangaea Oncology isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Pangaea Oncology's main competitors or similar companies to consider before investing?
When looking at Pangaea Oncology, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Clinica Baviera S.A
CBAV832.96M Healthcare Diagnostics & Research 49.86% 175.86% EuroEspes S.A
EEP6.22M Healthcare Diagnostics & Research 0.00% 0.00% Grifols, S.A
GRF6.09B Healthcare Drug Manufacturers - General 5.17% -3.97% Laboratorios
ROVI4.34B Healthcare Drug Manufacturers - Specialty & Generic 58.55% 101.84% Almirall S.A
ALM2.76B Healthcare Drug Manufacturers - Specialty & Generic 31.68% 36.63% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Pangaea Oncology S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Pangaea Oncology's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -29.97%, the Debt to Equity ratio from the most recent quarter is 23.04, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for PANG?
- Looking at Pangaea Oncology's growth, its revenue over the trailing twelve months (TTM) was €14M. Compared to the same quarter last year (YoY), quarterly revenue grew by 139.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of PANG stock is held by insiders and institutions?
- Wondering who owns Pangaea Oncology stock? Company insiders (like executives and directors) hold about 69.32% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.